| Condition |
Trial Name |
| Bladder Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer, Endometrial Cancer, Renal Cell Carcinoma, Rectal Cancer |
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation |
| Breast Cancer |
ELEVATE: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer |
| Breast Cancer |
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer |
| Breast Cancer |
INAVO-123: A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer |
| Breast Cancer |
KANDELA-302: BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease |
| Breast Cancer |
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial |
| Breast Cancer |
optiNAVO: A Phase II, Randomized, Open-label Study Evaluating Two Invaolisib Dose Levels in Combination With Fulvestrant in Participants with PIK3CA-mutated, HR-postive, HER2-negative Locally Advanced or Metastatic Breast Cancer |
| Breast Cancer |
EmpowHER 208: A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer |
| Breast Cancer |
ASCENT-05: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy |
| Breast Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer, Ovarian Cancer, Urothelial Cancer, Sarcoma, Thyroid Cancer |
A Phase 1 Dose-Escalation Study of SLV-154 in Subjects With Metastatic Solid Tumors |
| Breast Cancer, Non-small Cell Lung Cancer, Urothelial Carcinoma |
Phase 1/2, Open-label, Multicenter, First-in-Human Study of DS-3939a in Subjects With Advanced Solid Tumors |
| CLL/SLL |
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| CLL/SLL |
Transcend-CLL: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) |
| CLL/SLL, Marginal Zone Lymphoma, Richter's transformation |
Bellwave-003: A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies |
| Colorectal Cancer |
OrigAMI-3: A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy |
| Colorectal Cancer |
OrigAMI-2: A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer |
| Colorectal Cancer |
androMETa-CRC560: A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer |
| DLBCL |
Alpha3: A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma |
| Gastric Cancer |
CLARITY-Grastic02: Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 |
| Multiple Myeloma |
TRIlogy-5: A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma |
| Multiple Myeloma |
MajesTEC-7 - A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma |
| Non Small Cell Lung Cancer |
androMETa-Lung-713: A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer |
| Non-small Cell Lung Cancer |
KRYSTAL-7: Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation |
| Non-small Cell Lung Cancer |
PACIFIC-8: A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC |
| Non-small Cell Lung Cancer |
PRESERVE-003: Study of Gotistobart (ONC-392/BNT316) vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer |
| Non-small Cell Lung Cancer |
TeliMET-NSCLC04: A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
| Non-small Cell Lung Cancer |
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation |
| Non-small Cell Lung Cancer |
Rosetta-Lung02: Safety, Effectiveness, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer |
| Non-small Cell Lung Cancer |
AndroMETA-Lung-536: A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations |
| Non-small Cell Lung Cancer |
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer |
| Non-small Cell Lung Cancer |
MK-2870-009: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors |
| Non-small Cell Lung Cancer |
RAINFOL-05: A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer |
| Pancreatic Cancer |
TRIDENT: Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma |
| Prostate Cancer |
KLK2-PASenger: A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer |
| Prostate Cancer |
PARTIQoL: Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer |
| Prostate Cancer |
AcTFirst: Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC |
| Renal Cell Carcinoma, Urothelial Carcinoma |
STELLAR-002: Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors |
| Small Cell Lung Cancer |
IDeate-Lung02: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
| Small Cell Lung Cancer |
IDeate-Lung03: A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer |
| Solid Tumor |
VINCIT: Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo in Patients With Cancer-associated Cachexia |
| Solid Tumors |
IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Chemotherapy With Advanced Compression Technology - A Safety and Efficacy Study |
| Solid tumor |
Registry Study for Radiation Therapy Outcomes |
| Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy(ies), Systemic Sclerosis |
Resolution: A Phase 1 Study Evaluating The Safety And Preliminary Efficacy of ALLO-329, A Dual Anti-CD19/Anti-CD70 Allogeneic CAR T Cell Production in Autoimmune Disease |
| Urothelial Carcinoma |
TROPION-PanTumor03: A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours |
